Chemify Limited raises $50m in Series B funding for AI-driven chemistry platform

OneBio: A Beacon of Bio-Innovation 🌍 Founded by Michael Fichardt and Dr. Nick Walker, OneBio Innovation Centre is driving biotech growth through venture investment, hands-on lab spaces, and strong partnerships with local universities. From its Innovation Centre in Salt River, OneBio is shaping the future of biotech - right here in the Mother City. Watch more here: https://shorturl.at/ZAE6Z #InvestCapeTown #OneBio #BioInnovation #EconomicGrowth #Biotech

Forbion Successfully Closes Its Bioeconomy Fund I 🚀 In the world of life sciences investments, Forbion has marked a milestone by closing its first fund dedicated to bioeconomy, Bioeconomy Fund I, with an oversubscribed raise that reached the hard cap of 200 million euros 💼. Key details of the announcement 📊: - The fund focuses on investment opportunities in sustainable biotechnology, innovation in bioeconomy, and solutions for global challenges such as the green transition and health. - Forbion, with more than 25 years of experience in the sector, attracted institutional investors and family offices from Europe and beyond, exceeding the initial expectations of 150 million euros. - The first investments are already underway, targeting startups and early-stage companies that drive the circular economy and decarbonization 🌱. This closure reflects the growing interest in bioeconomy as a driver of responsible growth, aligned with ESG objectives and the UN's 2030 Agenda. For Forbion, it represents a strategic expansion of its portfolio, which already manages more than 4 billion euros in assets. For more information, visit: https://lnkd.in/ec8sVSZX #Bioeconomy #SustainableInvestments #LifeSciences #Fintech #ESG #GreenInnovation If you're passionate about the impact of innovation in bioeconomy, consider donating to Enigma Security to keep bringing news like this: https://lnkd.in/er_qUAQh Connect with me on LinkedIn to discuss trends in investment and technology: https://lnkd.in/eXXHi_Rr 📅 Wed, 05 Nov 2025 12:10:07 +0000 🔗Subscribe to the Membership: https://lnkd.in/eh_rNRyt

Forbion Successfully Closes Its Bioeconomy Fund I 🚀 In the world of life sciences investments, Forbion has marked a milestone by closing its first fund dedicated to bioeconomy, Bioeconomy Fund I, with an oversubscribed raise that reached the hard cap of 200 million euros 💼. Key details of the announcement 📊: - The fund focuses on investment opportunities in sustainable biotechnology, innovation in bioeconomy, and solutions for global challenges such as the green transition and health. - Forbion, with more than 25 years of experience in the sector, attracted institutional investors and family offices from Europe and beyond, exceeding the initial expectations of 150 million euros. - The first investments are already underway, targeting startups and early-stage companies that drive the circular economy and decarbonization 🌱. This closure reflects the growing interest in bioeconomy as a driver of responsible growth, aligned with ESG objectives and the UN's 2030 Agenda. For Forbion, it represents a strategic expansion of its portfolio, which already manages more than 4 billion euros in assets. For more information, visit: https://lnkd.in/eJhE26Kh #Bioeconomy #SustainableInvestments #LifeSciences #Fintech #ESG #GreenInnovation If you're passionate about the impact of innovation in bioeconomy, consider donating to Enigma Security to keep bringing news like this: https://lnkd.in/evtXjJTA Connect with me on LinkedIn to discuss trends in investment and technology: https://lnkd.in/ex7ST38j 📅 Wed, 05 Nov 2025 12:10:07 +0000 🔗Subscribe to the Membership: https://lnkd.in/eh_rNRyt

ATDev Secures $3 Million Seed Investment to Scale Assistive Mobility Ecosystem https://lnkd.in/gAvRbAiU ORANGE, Calif., Oct. 16, 2025 /PRNewswire/ — Assistive Technology Development, Inc. (ATDev), a pioneer in AI-enabled, high-performance rehabilitation and personal mobility solutions, announced today that it has raised $3 million in Seed funding. The round [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

Chemify Limited, a Glasgow, Scotland-based deep-tech company founded and led by CEO Lee Cronin, raised over $50 million in an oversubscribed Series B co-led by Wing Venture Capital and Insight Partners, with participation from 8VC, Triatomic Capital, BlueYard Capital, Rockspring, and EOS Group. The funding will accelerate global expansion of Chemify’s Chemputation platform and Chemifarm facilities, advancing its mission to digitize molecule creation and transform how medicines and advanced materials are designed and manufactured. Founded in 2022 as a University of Glasgow spin-out, Chemify is pioneering the fusion of AI, robotics, and chemistry to enable on-demand molecular design and synthesis worldwide. FOUNDER: Lee Cronin INVESTORS: Wing Venture Capital, Insight Partners, 8VC, Triatomic Capital, Blueyard, Rockspring & Eos ROUND: Series B AMOUNT: $50,000,000 HQ: #Glasgow #Scotland #VentureCapital #Chemify #WingVentureCapital #InsightPartners #8VC #TriatomicCapital #Blueyard #Rockspring #Eos #LeeCronin #TradedVC

🔶️ #Biotech Capital 2025: Europe’s Selective Comeback Public windows stay closed, yet #Europe’s best #biotechfunds are #raising record rounds — Sofinnova (€1.2B) and Biovelocita II (€165M) among them. The paradox? There’s #capitalabundance for the #few, and scarcity for everyone else. 🎯The game has shifted from funding science to #buildingcompanies. VCs now want #founderoperators who can translate discovery into #revenue models, #regulatory milestones, and #exits — not just data. ⬆️ For CFOs and founders, this means #reframing fundraising: align your #thesis to a fund’s #operatingDNA. ‼️A digital-therapeutic play? Think corporate-VC hybrids like Lilly × a16z. #Platformbiology? Look at Sofinnova or Forbion’s BioEconomy model. 💪It’s not about raising faster — it’s about raising fit. 🇪🇺 Europe’s #biotech is becoming #selective, not smaller. ❓️How ready are we to treat capital as a design variable, not a constraint? BE-COME https://lnkd.in/dvUyCca8

Australia is globally recognised for its world-class research in the life sciences sector – but experts say the industry remains small on a global scale and needs greater capital investment to help companies scale. Today’s AusBiotech Invest 2025 forum in Melbourne brings together investors and 23 presenting companies, ahead of its international conference starting tomorrow. Nadine McGrath talks to experts ahead of Ausbiotech Invest 2025 about where more investment support is needed and the opportunities for Australia to continue growing its life sciences sector: https://buff.ly/aVKtJng #health #biotech #ASX

Out now: What’s Next in Biotech, in conversation with Venrock Partner Bryan Roberts. In this conversation, Gunderson Dettmer Partner and Chair of the Life Sciences practice, Tim Ehrlich, sits down with Bryan Roberts, Partner at Venrock, to discuss the shifting dynamics shaping the life sciences sector. The discussion covers critical issues, including how companies and investors are navigating current market conditions, evolving fundraising strategies, the growing influence of AI in biotech and how Venrock is managing its $650 million fund raised in 2024. Watch the full episode for timely insights into where innovation, capital and strategy intersect across the biotech landscape and share your thoughts on who we should feature next. WATCH HERE: https://lnkd.in/gn4arxn4 What’s Next in Biotech, developed by Gunderson Dettmer Partner Tim Ehrlich, features conversations with proven leaders in the life sciences industry to generate insights on market conditions and key drivers for building the next generation of successful biotech companies. #biotech #lifesciences #venturecapital #innovation #biotechnology #gundersondettmer

We believe that our role as a business is so much more than just providing sequencing services that help you to find new treatments, make new discoveries and power the bioeconomy of tomorrow. We envision a global economy that uses business as a force for good. - We are helping to build communities of researchers and innovators, supporting the London SynBio Network and Nucleate UK. - We are improving access to high quality research services, starting with our partnership with Field Foundry and their HPLC services. - It shouldn't cost the earth to get some sequencing results and we are here to change that! We consider our environmental impact in the decisions that we make, opting for low impact laboratory consumables and recycling (almost) everything through RecycleLab. We also use low impact forms of transportation for your samples (because airplanes shouldn't be necessary just to get some data). - We're proud to work together with grassroots environmental charities and have committed to donating 1% of our revenue through the 1% for the Planet programme. This past year we supported Fundación Montecito, a Colombian charity that works on helping communities coexist in harmony with their local ecosystem through cultural and educational programmes. There is a common theme running through our work inside and outside the lab. We don't believe that we can or should do it alone. As a proud #BCorp we will use the words of B Lab in their Declaration of Interdependence, "We are dependent upon one another and thus responsible for each other and future generations." Today we are launching our new Full Circle Labs branding. It represents a new beginning for us, allowing us to look back on where we started but also looking to the future and what we are building together as a community. We're much more than just a sequencing company, we're the driving force behind a more socially and environmentally responsible biotech future. Let's build a better (biotech) future together!

Ontario’s life sciences ecosystem is getting a new boost with the launch of Life Sciences Central, a joint initiative from MaRS Discovery District, OBIO and TIAP - Toronto Innovation Acceleration Partners designed to streamline commercialization pathways and reduce ecosystem fragmentation. Read more at https://buff.ly/t9BlRR7. #LifeSciences #Biotech #HealthTech #CanadianHealthTech #OntarioLifeSciences